Skip to main content

New Treatment Triggers Self-Destruction of Pancreatic Cancer Cells

Written on |
Research conducted on human pancreatic tumours transplanted in mice reveals promising results, TAU researchers say Pancreatic cancer is resistant to all current treatments. Patients have extremely poor chances of surviving for five years after being diagnosed. A new Tel Aviv University study finds that a small molecule has the ability to induce the self-destruction of pancreatic cancer cells. The research was conducted with xenografts — transplantations of human pancreatic cancer into immunocompromised mice. The treatment reduced the number of cancer cells by 90% in the developed tumors a month after being administered. The research holds great potential for the development of a new effective therapy to treat this aggressive cancer in humans. The study was led by Prof. Malca Cohen-Armon and her team at TAU’s Sackler Faculty of Medicine, in collaboration with Dr. Talia Golan’s team at the Cancer Research Center at Sheba Medical Center. It was published in the journal Oncotarget on October 22. “In research published in 2017, we discovered a mechanism that causes the self-destruction of human cancer cells during their duplication (mitosis) without affecting normal cells,” explains Prof. Cohen-Armon. “We have now harnessed this information to efficiently eradicate human pancreatic cancer cells in xenografts. The current results were obtained using a small molecule that evokes this self-destruction mechanism in a variety of human cancer cells. “The mice were treated with a molecule called PJ34, which is permeable in the cell membrane but affects human cancer cells exclusively. This molecule causes an anomaly during the duplication of human cancer cells, provoking their rapid cell death. Thus, cell multiplication itself resulted in cell death in the treated cancer cells.” A month after being injected with PJ34 daily for 14 days, the pancreatic cancer cells in the tumors of the treated mice experienced a relative drop of 90%. In one mouse, the tumor completely disappeared. “It is important to note that no adverse effects were observed, and there were no changes in the weight gain of the mice, nor in their behavior,” says Prof. Cohen-Armon. This mechanism acts efficiently in other types of cancer resistant to current therapies. The molecule PJ34 is being tested in pre-clinical trials according to FDA regulations before clinical trials begin.  

Related posts

Destroying Cancer: new drug delivery system containing RNA therapy can target cancer cells in bone marrow

31 July 2023

Stress Makes Vaccines Less Effective

26 July 2023

Researchers Induce Cancer Cell “Suicide”

17 July 2023

Metabolomics – A New Frontier in Preventive Medicine

13 July 2023

Older Bats do Suffer from Age-related Hearing Loss

13 July 2023

Operation Guardian of the Walls: Women, Young People and Residents of the South Paid the Heaviest Price

12 July 2023

Discovery May Lead to Personalized Medicine for Infectious Diseases

12 July 2023

One Third of Normal-Weight Individuals are Obese

12 July 2023

Breakthrough Gene Therapy Offers Hope for Severe Developmental Epilepsy in Children

27 June 2023

Prof. Isaac P. Witz Honored with 2023 Szent-Györgyi Prize for Progress in Cancer Research

26 June 2023

A Step Closer to Beating Melanoma?

18 June 2023

Imagining the Future Patient

13 June 2023

New Treatment Reduces ADHD Symptoms in 1 out of 3 Students

13 June 2023

“Hope Is Like the Air We Breathe”

11 June 2023

The Power of Sleep

7 June 2023

Prof. Yosef Shiloh Elected as International Member of US National Academy of Sciences

18 May 2023

Victoria

Tok Corporate Centre, Level 1,
459 Toorak Road, Toorak VIC 3142
Phone: +61 3 9296 2065
Email: [email protected]

New South Wales

Level 22, Westfield Tower 2, 101 Grafton Street, Bondi Junction NSW 2022
Phone: +61 418 465 556
Email: [email protected]

Western Australia

P O Box 36, Claremont,
WA  6010
Phone: :+61 411 223 550
Email: [email protected]